KALVISTA PHARMACEUTICALS
KalVista Pharmaceuticals is an ophthalmology company with a focus on diabetic macular edema (DME). KalVista is developing novel plasma kallikrein inhibitors, which represents a new approach to the treatment of DME, a leading cause of adult visual loss in developed countries. KalVista has an advanced pre-clinical product pipeline resulting from over 20 years of leading pharmaceutical discovery in the field of serine protease inhibitors and is targeting both intravitreal injection and oral adminis... tration. Although VEGF inhibitors clearly can benefit DME, a significant number of patients do not respond fully to these agents and have limited treatment options. Plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option.
KALVISTA PHARMACEUTICALS
Industry:
Biotechnology Diabetes Health Care
Founded:
2011-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.kalvista.com
Total Employee:
11+
Status:
Active
Contact:
(857) 999 0075
Email Addresses:
[email protected]
Total Funding:
239.7 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Google Tag Manager Google Universal Analytics Global Site Tag Nginx
Similar Organizations
Gelesis
Gelesis is a biotechnology company developing first-in-class therapeutics to safely treat obese, overweight, and diabetic patients.
Milestone Pharmaceuticals
Milestone Pharmaceuticals is a drug development company developing small molecule therapeutics for the treatment of cardiovascular diseases.
NovaBay Pharmaceuticals
NovaBay Pharmaceuticals is a biopharmaceutical company developing products for the eye care market.
Ribon Therapeutics
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2016-06-15 | Carbylan Therapeutics | Carbylan Therapeutics acquired by KalVista Pharmaceuticals | N/A |
Investors List
Longwood Fund
Longwood Fund investment in Series B - KalVista Pharmaceuticals
Venrock
Venrock investment in Series B - KalVista Pharmaceuticals
Novo Holdings
Novo Holdings investment in Series B - KalVista Pharmaceuticals
SV Health Investors
SV Health Investors investment in Series B - KalVista Pharmaceuticals
RA Capital Management
RA Capital Management investment in Series B - KalVista Pharmaceuticals
Novo Holdings
Novo Holdings investment in Series A - KalVista Pharmaceuticals
SV Health Investors
SV Health Investors investment in Series A - KalVista Pharmaceuticals
Key Employee Changes
| Date | New article |
|---|---|
| 2021-05-03 | KalVista bulks up executive team with CMO addition as angioedema franchise grinds to launch |
Official Site Inspections
http://www.kalvista.com Semrush global rank: 1.92 M Semrush visits lastest month: 11.32 K
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
